AstraZeneca Plc (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) on Tuesday shared full results from the Phase 3 CROSSING trial of Tezspire (tezepelumab) in adolescents and adults with uncontrolled eosinophilic esophagitis (EoE).
EoE is a chronic, immune-mediated inflammatory disease where white blood cells called eosinophils build up in the lining of the esophagus (a muscular tube that connects the throat to the stomach to transport food and liquid), causing damage and difficulty swallowing. Both tested doses met the co-primary endpoints by delivering statistically significant improvements in histologic remission and swallowing difficulties at week 24 compared to placebo, with benefits enduring through week 52.
Researchers presented the findings during a late-breaking oral presentation at United European Gastroenterology Week 2026. Read Also: Oracle Joins Forces With AstraZeneca to Put AI to Work in Drug Research Significant Remission and Symptom Reductions The companies shared topline data from the trial in August.
5% for placebo. 7 points in the placebo arm.
These gains persisted over the 52-week evaluation period. 4% for placebo.
2 points for placebo. Endoscopic Remission and Safety Profile Tezspire also demonstrated significant improvements in endoscopic features at weeks 24 and 52.
1% for placebo. Tezspire demonstrated a safety profile consistent with its approved indications, with nasopharyngitis, headache, and diarrhea occurring most frequently.
The drug already holds approvals for severe asthma and chronic rhinosinusitis with nasal polyps, while Phase 3 trials in chronic obstructive pulmonary disease continue. 30 at the time of publication on Tuesday, according to Benzinga Pro data.
